Johnson & Johnson's antipsychotic Caplyta has notched its first phase 3 win in bipolar-associated manic episodes, according to a company announcement. The trial's success puts the drug on track for a broader psychiatric label, potentially covering acute mania in addition to its existing uses for schizophrenia and bipolar depression.
The positive readout comes as J&J's $14.6 billion bet on Intra-Cellular Therapies continues to pay off. Caplyta has already reached blockbuster sales status, and this new indication could further expand its market. The company said it plans to discuss the data with regulators, though no specific timeline for a submission was given in the source.
Because there is only one source, there are no conflicting accounts to reconcile. The source frames the result as a firm step forward, but notes that the trial is the first phase 3 win for this specific indication, leaving room for additional regulatory hurdles before approval.